These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinson's Disease. Johnson WM; Golczak M; Choe K; Curran PL; Miller OG; Yao C; Wang W; Lin J; Milkovic NM; Ray A; Ravindranath V; Zhu X; Wilson MA; Wilson-Delfosse AL; Chen SG; Mieyal JJ Biochemistry; 2016 Aug; 55(32):4519-32. PubMed ID: 26894491 [TBL] [Abstract][Full Text] [Related]
5. Glutaredoxin 1 Downregulation in the Substantia Nigra Leads to Dopaminergic Degeneration in Mice. Verma A; Ray A; Bapat D; Diwakar L; Kommaddi RP; Schneider BL; Hirsch EC; Ravindranath V Mov Disord; 2020 Oct; 35(10):1843-1853. PubMed ID: 32618039 [TBL] [Abstract][Full Text] [Related]
6. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485 [TBL] [Abstract][Full Text] [Related]
7. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Yao C; El Khoury R; Wang W; Byrd TA; Pehek EA; Thacker C; Zhu X; Smith MA; Wilson-Delfosse AL; Chen SG Neurobiol Dis; 2010 Oct; 40(1):73-81. PubMed ID: 20382224 [TBL] [Abstract][Full Text] [Related]
8. Regulation of TIR-1/SARM-1 by miR-71 Protects Dopaminergic Neurons in a Naidoo D; de Lencastre A Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201481 [TBL] [Abstract][Full Text] [Related]
9. The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of α-synuclein in C. elegans. Bornhorst J; Chakraborty S; Meyer S; Lohren H; Brinkhaus SG; Knight AL; Caldwell KA; Caldwell GA; Karst U; Schwerdtle T; Bowman A; Aschner M Metallomics; 2014 Mar; 6(3):476-90. PubMed ID: 24452053 [TBL] [Abstract][Full Text] [Related]
10. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Yao C; Johnson WM; Gao Y; Wang W; Zhang J; Deak M; Alessi DR; Zhu X; Mieyal JJ; Roder H; Wilson-Delfosse AL; Chen SG Hum Mol Genet; 2013 Jan; 22(2):328-44. PubMed ID: 23065705 [TBL] [Abstract][Full Text] [Related]
11. Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans. Yuan Y; Cao P; Smith MA; Kramp K; Huang Y; Hisamoto N; Matsumoto K; Hatzoglou M; Jin H; Feng Z PLoS One; 2011; 6(8):e22354. PubMed ID: 21857923 [TBL] [Abstract][Full Text] [Related]
12. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis. Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355 [TBL] [Abstract][Full Text] [Related]
13. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Liu Z; Hamamichi S; Lee BD; Yang D; Ray A; Caldwell GA; Caldwell KA; Dawson TM; Smith WW; Dawson VL Hum Mol Genet; 2011 Oct; 20(20):3933-42. PubMed ID: 21768216 [TBL] [Abstract][Full Text] [Related]
15. Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder. Calahorro F; Ruiz-Rubio M Invert Neurosci; 2011 Dec; 11(2):73-83. PubMed ID: 22068627 [TBL] [Abstract][Full Text] [Related]
16. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. Henderson MX; Peng C; Trojanowski JQ; Lee VMY Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356 [TBL] [Abstract][Full Text] [Related]
17. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons. Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882 [TBL] [Abstract][Full Text] [Related]
18. Modeling Parkinson's disease using induced pluripotent stem cells. Byers B; Lee HL; Reijo Pera R Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490 [TBL] [Abstract][Full Text] [Related]